Blood biomarkers in ALS: challenges, applications and novel frontiers.
Ontology highlight
ABSTRACT: Amyotrophic lateral sclerosis (ALS) is the most common motor neuron disease among adults. With diagnosis reached relatively late into the disease process, extensive motor cell loss narrows the window for therapeutic opportunities. Clinical heterogeneity in ALS and the lack of disease-specific biomarkers have so far led to large-sized clinical trials with long follow-up needed to define clinical outcomes. In advanced ALS patients, there is presently limited scope to use imaging or invasive cerebrospinal fluid (CSF) collection as a source of disease biomarkers. The development of more patient-friendly and accessible blood biomarker assays is hampered by analytical hurdles like the matrix effect of blood components. However, blood also provides the opportunity to identify disease-specific ada
SUBMITTER: Sturmey E
PROVIDER: S-EPMC9828487 | biostudies-literature | 2022 Oct
REPOSITORIES: biostudies-literature
ACCESS DATA